+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 70Years +
All Genders
ID04305834

Evaluating Abemaciclib Tolerability With Endocrine Therapy in Patients Aged 70 and Older With Metastatic Hormone Receptor Positive Breast Cancer

Led by City of Hope Medical Center · Updated on 2026-10-16

43

Participants Needed

6

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying abemaciclib monotherapy in patients aged 70 years and older who have hormone receptor positive, HER2 negative metastatic breast cancer. This phase IIa trial aims to estimate the occurrence of serious toxic side effects, describe the full range of side effects including patient-reported ones, and assess treatment adherence and survival outcomes. The study also explores the relationship between geriatric assessment scores, biomarkers of aging, and toxicity. Participants receive abemaciclib orally twice daily for 28-day cycles, continuing until disease progression or unacceptable side effects occur. After treatment ends, participants are followed up at 30 days and then every 6 months for two years to monitor long-term effects and survival. Ancillary studies include questionnaire assessments and blood tests to measure drug levels and biomarkers. Throughout the study, participants undergo regular evaluations including toxicity assessments, dose adjustments, hospitalizations, and quality of life questionnaires. Researchers collect data on progression-free survival and overall survival up to two years post-treatment. Safety monitoring continues for up to 30 days after treatment completion, with additional follow-up visits to assess long-term outcomes and treatment utility.

CONDITIONS

Brief Title

Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.

Research Team

J

Joanne Mortimer, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here